Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.

被引：0
|
作者：
Meluch, AA
Spigel, DS
Greco, FA
Barton, JH
Messina, G
Gould, B
Rovito, MA
Hainsworth, JD
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Wellstar Hlth Syst Canc Res, Marietta, GA USA
[3] Consultants Med Oncol & Hematol, Drexel Hill, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：436S / 436S
页数：1
相关论文
共 50 条
  • [1] Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A minnie pearl cancer research network phase II trial
    Hainsworth, John D.
    Meluch, Anthony A.
    Spigel, David R.
    Barton, John, Jr.
    Simons, Lisa
    Meng, Christina
    Gould, Bruce
    Greco, E. Anthony
    CLINICAL GENITOURINARY CANCER, 2007, 5 (04) : 278 - 283
  • [2] Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial
    Hainsworth, JD
    Burris, HA
    Yardley, DA
    Bradof, JE
    Grimaldi, M
    Kalman, LA
    Sullivan, T
    Baker, M
    Erland, JB
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) : 3500 - 3505
  • [3] Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma - A phase 2 trial of the Minnie Pearl Cancer Research Network
    Hainsworth, John D.
    Spigel, David R.
    Barton, John
    Farley, Cindy
    Schreeder, Marshall
    Hon, Jeremy
    Greco, F. Anthony
    CANCER, 2008, 113 (04) : 765 - 771
  • [4] Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma -: A Minnie Pearl Cancer Research Network Phase II trial
    Hainsworth, JD
    Burris, HA
    Litchy, S
    Morrissey, LH
    Barton, JH
    Bradof, JE
    Greco, FA
    CANCER, 2000, 89 (02) : 328 - 333
  • [5] Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Meluch, AA
    Greco, FA
    Burris, HA
    Erland, JB
    Khan, RA
    Rodriguez, GI
    Gandhi, JG
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 421S - 421S
  • [6] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [7] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [8] Phase I/II study of weekly docetaxel and vinblastine in the treatment of hormone-refractory prostate cancer (HRPC).
    Ackler, JR
    Tester, WJ
    Leighton, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 771S - 771S
  • [9] Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network.
    Greco, F. A.
    Spigel, D. R.
    Barton, J. H.
    Farley, C.
    Schreeder, M. T.
    Hermann, R. C.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 433S - 433S
  • [10] Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma - Results of a Minnie Pearl Cancer Research Network Phase II Trial
    Meluch, AA
    Greco, FA
    Morrissey, LH
    Raefsky, EL
    Steis, RG
    Butts, JA
    Hainsworth, JD
    CANCER, 2003, 98 (10) : 2192 - 2198
12345